Loading...
TCX is not a good buy right now. Price is sitting just above key support (~22.27) while momentum remains bearish (MACD histogram negative and worsening). With hedge funds aggressively selling and no Intellectia buy signals, the near-term setup favors further downside or, at best, an unreliable oversold bounce—unattractive for an impatient buyer.
Trend/momentum: Bearish. MACD histogram is -0.312 and negatively expanding, indicating weakening momentum. RSI(6) is 28.4, which is oversold/near-oversold—this can spark short bounces, but it is not a reversal signal by itself.
Structure/levels: Current post-market price ~22.22 is right on S1 (22.271). A clean break below ~22.27 increases risk toward S2 (21.47). Bulls need to reclaim the pivot (~23.57) to improve the short-term trend; resistance above sits at ~24.87 then ~25.68.
Pattern/stat bias: Similar-pattern stats suggest small upside next day/week but negative over the next month (-3.04%), aligning with the bearish momentum read.

could produce a quick mean-reversion bounce.
is modestly bullish on positioning.
Hedge funds are selling aggressively (selling amount up ~3294% last quarter), a strong negative flow signal.
Latest quarter: 2025/Q3. Revenue rose to ~$98.56M (+6.78% YoY), but profitability remains weak: net income was still deeply negative at about -$23.02M (only a modest improvement YoY), EPS -2.08. Gross margin declined to ~23.74% (-1.17% YoY), suggesting pressure on unit economics despite revenue growth.
No analyst rating or price target change data was provided, so a current Wall Street consensus view (pros/cons) cannot be confirmed from the dataset. From the available data, the major 'pro' would be revenue growth and potential oversold bounce; the major 'cons' are ongoing losses, declining gross margin, and heavy hedge-fund selling.
